JEFFREY WINSTON: Open Payments
NPI 1003938598 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,979 in 186 payments from 22 companies in 2025. Trend: 2023 $2,959 · 2024 $2,751 · 2025 $3,979
Food & beverage: $3,859Education: $120
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 17 | $399 |
| Axsome Therapeutics, Inc. | 11 | $380 |
| Janssen Pharmaceuticals, Inc | 16 | $370 |
| Alkermes, Inc. | 15 | $340 |
| Otsuka America Pharmaceutical, Inc. | 17 | $309 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $305 |
| Tris Pharma Inc | 10 | $292 |
| ABBVIE INC. | 15 | $242 |
| Vanda Pharmaceuticals Inc. | 10 | $205 |
| Bausch Health US, LLC | 12 | $198 |
Products named: REXULTI, Qelbree, Auvelity, CAPLYTA, ARISTADA, VRAYLAR, FANAPT, SPRAVATO.
Industry payments across GA — which companies pay providers there.
